X

Trial Profile

Phase I/IIa trial of 7HP349 in patients with PD-1 checkpoint inhibitor resistant solid tumors

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 25 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alintegmod (Primary)
Indications Solid tumours
Focus Therapeutic Use
Sponsors 7 Hills Pharma

Most Recent Events

22 May 2023 According to 7 Hill Pharma media release, the company as been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance 7HP349 into this trial.
09 Nov 2020 According to 7 Hill Pharma media release, company expects to move into this trial in next year (2021).
24 Sep 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com